An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

The present invention features novel methods for the cryopreservation of mammalian cell that combine the advantages of the slow-freezing and vitrification approaches while avoiding their shortcomings. Generally, the methods include the use of a capillary tube made of a thermally conductive wall material and a thin wall such that the ratio of the thermal conductivity of the wall material to the wall thickness is at least 1,000-500,000. The solution is then exposed to temperatures equal to or less than 80 C. and the vitrification solution containing the mammalian cells is cooled at a rate equal to or greater than 30,000-100,000,000 C./minute. The exposure of the capillary tube with a thermally conductive and thin wall allows for vitrification of the solution in the absence of ice formation. Cryoprotectants can also be added to the vitrification solution to further prevent ice formation.

The present technology provides methods for preparing a flowable amniotic composition derived from amniotic membrane of humans. Various embodiments of the method for preparing the amniotic composition may comprise mincing the amniotic membrane in a cryopreservation solution, cryopreservation, homogenization, filtration, centrifugation, and resuspension of a pellet in a cell solution to produce the flowable amniotic composition. The amniotic composition may comprise approximately 2.7 million viable cells per milliliter. The viability of the cells may be substantially stable for at least six months at 18 C. Some preparations of the amniotic composition may have a flowability that may be at least partially characterized by a viscosity suitable for delivery to the target site through at least a 22 gauge needle.

Method of using a plasmalogen contained in a processed ascidian: freeze-drying a Halocynthia roretzi without encystment to obtain a processed ascidian; storing the processed ascidian at room temperature to 35 degrees C. for two months or more after the freeze drying; and using the processed ascidian stored for two months or more as described above to use a plasmalogen contained in the processed ascidian.

Cell culture systems and methods provide improved immunotherapeutic product manufacturing with greater scalability, flexibility, and automation. Cell culture systems are configured with interchangeable cartridges, allowing versatility and scalability. Systems are configured to have multiple connected cell culture chambers, which allows parallel processing of different types of cells. Gas-impermeable cell culture chambers and methods for generating cells in closed systems prevent contamination and user error. Methods for recycling cell culture medium provide additional efficiencies.

Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

A cryopreservation solution and use thereof in reducing an ischemia-reperfusion injury (IRI) of a cell, a tissue, or an organ, belonging to the technical field of cold storage or cryopreservation. By using innovative exploration mechanisms, it is found that phosphocholine, quinoline-4-carboxylic acid (QCA), and sodium tauroursodeoxycholate (TUDCA) have significant differences during a cryopreservation-rewarming period between hibernating and non-hibernating animals. Based on this, adding the phosphocholine, the QCA, and the TUDCA into a preservation solution to allow cryopreservation of cells, tissues, and/or organs shows a high cell survival rate, can effectively reduce apoptosis caused by cryopreservation-rewarming, reduce mitochondrial reactive oxygen species (ROS), maintain a cell membrane integrity, effectively reduce mitochondrial damage caused by cryopreservation-rewarming, reduce the IRI, and promote liver regeneration. This is of great significance to the advancement of organ transplantation and preservation.

Due to a rising demand in the need for organ transplantation and a critical donor organ shortage, the need to fill this gap has increased the use of ECD and donation after cardiac death (DCD) organs viable for transplantation to lower the mortality of patients on the organ waiting list. Described herein is a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.